HC Wainwright & Co. Reiterates Buy on Sagimet Biosciences, Maintains $29 Price Target
HC Wainwright & Co. analyst Brandon Folkes reiterates Sagimet Biosciences (NASDAQ:SGMT) with a Buy and maintains $29 price target.
Read original at benzingaStocks · News reference
Sagimet Biosciences Says FDA Cleared IND And Issued Study May Proceed Letter For Phase 3 Trial Of Denifanstat In Moderate To Severe Acne; Initiation On Track For 2H 2026
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 13, 2026, 11:06 AM
- Checked
- Aug 13, 2026, 11:06 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Sagimet Biosciences’ AURORA Phase 3 Clinical Trial Of FASN Inhibitor Denifanstat In Moderate To Severe Acne Is On Track To Initiate Enrollment In Q4 2026
All clinical trial sites identified and CRO retainedPatient screening expected to begin in October 2026,with first patient to be enrolled shortly afterFOSTER CITY, Calif., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Sagimet
Read original at benzingaSagimet Biosciences shares are trading higher after Citizens raised its price target on the stock from $12 to $29.
Read original at benzingaCitizens Maintains Market Outperform on Sagimet Biosciences, Raises Price Target to $29
Citizens analyst Jonathan Wolleben maintains Sagimet Biosciences (NASDAQ:SGMT) with a Market Outperform and raises the price target from $12 to $29.
Read original at benzinga